Environmental Protection Agency June 14, 2024 – Federal Register Recent Federal Regulation Documents
Results 1 - 4 of 4
Public Meetings of the Science Advisory Board Inorganic Arsenic Review Panel
The Environmental Protection Agency (EPA) Science Advisory Board (SAB) Staff Office announces three public meetings of the Science Advisory Board Inorganic Arsenic Review Panel. The purpose of the meetings is to review and discuss the panel's draft report of the EPA's draft IRIS Toxicological Review of Inorganic Arsenic.
Air Plan Approval; Nevada; Washoe County Health District
The Environmental Protection Agency (EPA) is proposing to approve a revision to the Washoe County portion of the Nevada State Implementation Plan (SIP). This revision concerns emissions of particulate matter (PM) from woodburning devices. We are proposing to approve a revision to a local rule that regulates these emission sources under the Clean Air Act (CAA or the Act). We are taking comments on this proposal and plan to follow with a final action.
n-Methylpyrrolidone (NMP); Regulation Under the Toxic Substances Control Act (TSCA)
The Environmental Protection Agency (EPA or the "Agency") is proposing to address the unreasonable risk of injury to human health presented by n-methylpyrrolidone (NMP) under its conditions of use as documented in EPA's risk evaluation and risk determination for NMP pursuant to the Toxic Substances Control Act (TSCA). NMP is a widely used solvent in a variety of industrial, commercial, and consumer applications including the manufacture and production of electronics such as semiconductors, polymers, petrochemical products, paints and coatings, and paint and coating removers. EPA determined that NMP presents an unreasonable risk of injury to health due to the significant adverse health effects associated with exposure to NMP, including developmental post-implantation fetal loss from short-term exposure and reduced fertility and fecundity from long-term exposure. Additional adverse effects associated with exposure to NMP include liver toxicity, kidney toxicity, immunotoxicity, neurotoxicity, skin irritation, and sensitization. To address the identified unreasonable risk, EPA is proposing to: prohibit the manufacture (including import), processing, and distribution in commerce and use of NMP in several occupational conditions of use; require worker protections through an NMP workplace chemical protection program (WCPP) or prescriptive controls (including concentration limits) for most of the occupational conditions of use; require concentration limits on a consumer product; regulate certain consumer products to prevent commercial use; and establish recordkeeping, labeling, and downstream notification requirements.
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.